Baxter International (BAX)
(Delayed Data from NYSE)
$37.54 USD
+1.05 (2.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Baxter International (BAX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.77 | $54.00 | $30.00 | 14.47% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Baxter International comes to $41.77. The forecasts range from a low of $30.00 to a high of $54.00. The average price target represents an increase of 14.47% from the last closing price of $36.49.
Analyst Price Targets (13)
Broker Rating
Baxter International currently has an average brokerage recommendation (ABR) of 2.62 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.62 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, three are Strong Buy, representing 21.43% of all recommendations. A month ago, Strong Buy represented 21.43%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BAX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 10 | 10 | 10 | 11 | 11 |
Sell | 1 | 1 | 1 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.62 | 2.62 | 2.62 | 2.57 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Hold | Hold |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Hold | Hold |
7/2/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Hold |
5/10/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Hold |
5/3/2024 | Not Identified | Not Identified | Hold | Hold |
2/8/2024 | UBS | Research Department | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.62 |
ABR (Last week) | 2.62 |
# of Recs in ABR | 14 |
Average Target Price | $41.77 |
LT Growth Rate | 10.00% |
Industry | Medical - Products |
Industry Rank by ABR | 99 of 253 |
Current Quarter EPS Est: | 0.77 |